B
Basilea Pharmaceutica
Commercial stage biopharmaceutical company
About Basilea Pharmaceutica
Basilea Pharmaceutica is a biopharmaceutical company based in Basel, Switzerland, and listed on the SIX Swiss Exchange under the ticker SIX BSLN. The company specializes in the research, development, and commercialization of innovative anti-infective treatments. Its core products, Cresemba and Zevtera, are aimed at addressing severe bacterial and fungal infections. Basilea primarily serves healthcare providers, hospitals, and clinics worldwide, focusing on markets with high unmet medical needs in infectious diseases. The company operates on a business model that combines in-house research and development with strategic partnerships and licensing agreements to bring its products to market. Revenue is generated through product sales, royalties, and milestone payments from partners.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2000
- Headquarters
- Allschwil, Switzerland
- Listing
- IPO 2004
- Sector
- Biotech & Life Sciences
- Power Law
- Thoroughbred$100M+ revenue
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
US Biomedical Advanced Research and Development Authority
CARB-X
Series B and later1 investor entered at this stage
Athyrium Capital Management
Source: Dealroom Talent Intelligence.
Global footprint
team presence
across markets
Patents
25 active patent families included in this estimate.
A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.
Market sentiment
An AI-synthesised read of the highest-engagement posts about Basilea Pharmaceutica on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Basilea Pharmaceutica on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.